Therapeutic genetic restoration through allogeneic brain microglia replacement

Area of Science:

• Neuroscience
• Immunology
• Regenerative Medicine

Background:

• Allogeneic hematopoietic stem and progenitor cells transplantation (HCT) shows promise for brain genetic disorders but has severe side effects.
• Myeloablative preconditioning and graft rejection limit current HCT efficacy for brain therapies.

Purpose of the Study:

• To develop a safer, more effective microglia replacement strategy for brain disorders.
• To investigate alternative cell sources and preconditioning methods for brain myeloid reconstitution.

Main Methods:

• Utilized intracerebral injection of Sca1-committed progenitor cells for microglia replacement.
• Developed brain-restricted preconditioning to avoid peripheral engraftment and associated complications.
• Evaluated therapeutic potential in a murine model of Sandhoff disease.
• Assessed engraftment potential of human induced pluripotent stem cell-derived myeloid progenitor cells.

Main Results:

• Sca1-committed progenitor cells efficiently replaced microglia without myeloablative preconditioning.
• Brain-restricted conditioning successfully avoided long-term peripheral engraftment and graft-vs-host disease.
• Allogeneic microglia replacement therapy rescued the murine model of Sandhoff disease.
• Human induced pluripotent stem cell-derived myeloid progenitor cells showed similar engraftment potential.

Conclusions:

• A brain-restricted, high-efficiency microglia replacement approach is feasible without myeloablative preconditioning.
• Committed progenitor cells are sufficient for brain myeloid reconstitution, offering a safer alternative to HCT.
• This strategy holds potential for developing allogeneic microglial cell therapies for lysosomal storage diseases and other brain disorders.